


PCLX-001

FIGURE 1




FIGURE 2A




FIGURE 2B




FIGURE 2C




FIGURE 2D




FIGURE 2E





FIGURE 2F


Patient 115-002-001



Pharmacokinetic analysis of patient 1 – day 1

FIGURE 3A


Patient 115-002-001



Pharmacokinetic analysis of patient 1 –day 15.

FIGURE 3B


Patient 115-002-002



PK analysis of Patient 2 – day 15 (right)

FIGURE 4A


Patient 115-002-002



PK analysis of Patient 2 –day 15

FIGURE 4B


Patient 115-002-004



PK analysis of patient 3. Day 1.


FIGURE 4C

Patient 115-002-004



PK analysis of patient 3. Day 15.


FIGURE 4D



Cycle, Day	Actual Pre-dose Concentration, ng/mL	Predicted Pre-dose Concentration, ng/mL
C1, Day 2	26.3	
C1, Day 8	34.2	
C1, Day 15	32.6	
C1, Day 22	51.4	
Steady State		38.12

Nonparametric Superposition Simulations to Steady State, Patient 1


FIGURE 5



Cycle, Day	Actual Pre-dose Concentration, ng/mL	Predicted Pre-dose Concentration, ng/mL
C1, Day 2	19.5	
C1, Day 8	37.6	
C1, Day 15	25.5	
C1, Day 22	34.6	
C2, Day1	36.1	
Steady State		22.78

Nonparametric Superposition Simulations to Steady State, Patient 2

FIGURE 6



Cycle, Day	Actual Pre-dose Concentration, ng/mL	Predicted Pre-dose Concentration, ng/mL
C1, Day 2	12.6	
C1, Day 8	11.4	
C1, Day 15	14.5	
C1, Day 22	24.5	
Steady State		13.79

Nonparametric Superposition Simulations to Steady State, Patient 3

FIGURE 7

Day 1 Dose Proportionality Analysis




FIGURE 8A

Day 1 Dose Proportionality Analysis




FIGURE 8B

Day 14 Dose Proportionality Analysis




FIGURE 9A



Day 14 Dose Proportionality Analysis
Day 14 AUClast/Dose vs Dose
PCLX-001 AUClast/Dose
400
350
300
250
200
150
100
50
0
-50
0
20
40
60
80
100
120
140
160
PCLX-001 Dose, mg
AUClast/Dose Day 15 wo/pantoprazole
AUClast/Dose Day 15 w/pantoprazole
AUClast/Dose Day 15 wo/pantoprazole
AUClast/Dose Day 15 w/pantoprazole

FIGURE 9B

Steady State Assessment for Subject Not On Pantoprozole




FIGURE 10

Plasma Concentrations of PCLX-001 after Oral Administration of PCLX-001 to Cancer Patients at 20 mg QD




FIGURE 11A

Plasma Concentrations of PCLX-001 after Oral Administration of PCLX-001 to Cancer Patients at 20 mg QD




FIGURE 11B

Plasma Concentrations of PCLX-001 after Oral Administration of PCLX-001 to Cancer Patients at 20 mg QD




FIGURE 11C

Plasma Concentrations of PCLX-001 after Oral Administration of PCLX-001 to Cancer Patients at 40 mg QD




FIGURE 12A



Plasma Concentrations of PCLX-001 after Oral Administration of PCLX-001 to Cancer Patients at 40 mg QD
Plasma PCLX-001, ng/mL
45
40
35
30
25
20
15
10
5
0
0
5
10
15
20
25
30
Time after Dose, hours
Patient 115-002-006, Day 1
Patient 115-002-006, Day 15
Patient 115-002-006, Day 15
Patient 115-002-006, Day 1

FIGURE 12B

Plasma Concentrations of PCLX-001 after Oral Administration of PCLX-001 to Cancer Patients at 40 mg QD




FIGURE 12C



Plasma Concentrations of PCLX-001 after Oral Administration of PCLX-001 to Cancer Patients at 70 mg QD
Plasma PCLX-001, ng/mL
700
600
500
400
300
200
100
0
0
5
10
15
20
25
30
Time after Dose, hours
115-002-007 Day 14
115-002-007 Day 1
115-002-007 Day 1
115-002-007 Day 14

FIGURE 13A



Plasma Concentrations of PCLX-001 after Oral Administration of PCLX-001 to Cancer Patients at 70 mg QD
Plasma PCLX-001, ng/mL
450
400
350
300
250
200
150
100
50
0
0
5
10
15
20
25
30
Time after Dose, hours
115-002-008 Day 14
115-002-008 Day 1
115-002-008 Day 1
115-002-008 Day 14

FIGURE 13B



Plasma Concentrations of PCLX-001 after Oral Administration of PCLX-001 to Cancer Patients at 70 mg QD
Plasma PCLX-001, ng/mL
1600
1400
1200
1000
800
600
400
200
0
0
5
10
15
20
25
30
Time after Dose, hours
115-024-001 Day 1
115-024-001 Day 14
115-024-001 Day 1
115-024-001 Day 14

FIGURE 13C

Plasma Concentrations of PCLX-001 after Oral Administration of PCLX-001 to Cancer Patients at 100 mg QD




FIGURE 14A




FIGURE 14B

Plasma Concentrations of PCLX-001 after Oral Administration of PCLX-001 to Cancer Patients at 100 mg QD




FIGURE 14C




FIGURE 14D

Plasma Concentrations of PCLX-001 after Oral Administration of PCLX-001 to Cancer Patients at 140 mg QD




FIGURE 15A



Plasma Concentrations of PCLX-001 after Oral Administration of PCLX-001 to Cancer Patients at 140 mg QD
Plasma PCLX-001, ng/mL
450
400
350
300
250
200
150
100
50
0
0
5
10
15
20
25
30
Time after Dose, Hours
Day 15 115-024-005
Day 1 115-024-005
Day 1 115-024-005
Day 15 115-024-005

FIGURE- 15B

Plasma Concentrations of PCLX-001 after Oral Administration of PCLX-001 to Cancer Patients at 140 mg QD




FIGURE 15C